• In collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen, BiondVax is developing a pipeline of NanoAb therapies
• The company’s co-lead scientific research collaborator, Professor Dr. Dirk Görlich, director at MPI, was awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his work describing protein transport within the cell
• The global market for autoimmune disorder therapies is expected to reach $90.7 billion by 2024; The global market for infectious disease therapeutics is expected to reach $167 billion by 2030

BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases – with a primary focus on diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma, and psoriasis. The company is developing a pipeline of innovative nanosized antibody (NanoAb) therapies in collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen (“UMG”), both in Germany. The NanoAb project’s co-lead scientific research collaborator, Professor Dr. Dirk Görlich, director at MPI, was recently awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his seminal work describing protein transport within the cell (https://ibn.fm/vxCaD). “I wish to offer my sincere congratulations to Dirk on being awarded the inaugural WLA Prize in Life Sciences. The award signals recognition and appreciation of his important research achievements and deep scientific acumen. His expertise extends to the unique and innovative NanoAb candidates being developed under our collaboration,” CEO Amir Reichman said, on behalf of the BiondVax team. “We look forward to forging ahead together with Dirk, Matthias, and their teams as we strive to bring a pipeline of NanoAb therapies that exhibit significant competitive advantages for conditions underserved by currently approved therapeutics.” BiondVax’s NanoAbs, also known as VHH-antibodies or nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production. BiondVax currently has an exclusive worldwide license for the development and commercialization of an inhaled COVID-19 NanoAb therapy, expected to enter clinical trials in 2023. BiondVax, Max Planck, and UMG also signed a broad five-year research collaboration in March 2022 under which BiondVax has exclusive options for similar worldwide licenses for NanoAbs addressing large market disorders currently underserved by approved therapeutic antibodies.  The agreement covers the discovery, development, and commercialization of NanoAbs therapies for indications such as asthma, psoriasis, macular degeneration, and psoriatic arthritis. The global market for autoimmune disorder therapies such as asthma, arthritis and psoriasis is expected to grow from $53.2 billion in 2019 to $90.7 billion by 2024, growing at a CAGR of 11.2% over the forecast period (https://ibn.fm/tTedJ). The global infectious disease therapeutics market is expected to grow from an estimated $119.87 billion in 2022 to $167 billion in 2030, growing at a CAGR of 4.23% (https://ibn.fm/DUAZ4). The primary factors driving key growth in these markets are the increased number of cases suffering from infectious and autoimmune diseases and the growing senior population. The company is in a unique position to advance NanoAb innovation from R&D through commercialization and offers a highly experienced and successful pharmaceutical industry leadership team that includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb. Since being founded BiondVax has executed eight clinical trials including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate. The company built, owns, and operates a 20,000-square-foot state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities, and offices. For more information, visit the company’s website at www.BiondVax.com. NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• The recent UN-sponsored COP27 Conference has highlighted the pressing need for significant climate-focused initiatives
• A UN panel led by Canada’s former environment minister has pushed for an urgent shift away from fossil fuels and towards renewable energy sources
• RNG platform operator, EverGen Infrastructure have been at the forefront of the renewable energy transformation taking place across both, the province of British Columbia and Canada as a whole
• The company has recently stated its goal to expand its production capacity to 20 locations across the country by 2025

The United Nations Framework Convention on Climate Change – better known as COP27 – is taking place in Egypt’s Sharm el-Sheikh amidst one of the most significant climate emergencies ever experienced by man. A growing energy crisis, record greenhouse gas (“GHG”) concentrations, and ever-increasing extreme weather events have significantly augmented the need for a coordinated, proactive global effort to combat global warming. The world has responded to a degree; 1,156 publicly listed companies, regions and cities have made net-zero pledges so far. Whilst promising on paper, several pledges have been a little more than vague commitments or proposals with scarce detail on how they will be implemented or tracked. In response, a United Nations advisory panel, led by Canada’s former environment minister Catherine McKenna, has called upon governments around the world to impose on companies to make serious net-zero emissions targets whilst simultaneously enforcing compliance, in an effort to ensure targets to slash emissions are adhered to (https://ibn.fm/m1xgH). In addition to the regulatory enforcement of net-zero targets, the UN panel offered recommendations on an array of other measures, including the phasing out of fossil fuels in conjunction with a fully funded shift to renewable energy sources, a change characterized as key towards the achievement of overarching climate goals. Ms. McKenna elaborated on the recommendation, “They [energy companies] have the means and the scale to be able to do big things on the renewables side, but they’re not even investing in these technologies.” British-Columbia based natural gas operator, EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) may be one of the outliers within McKenna’s assessment. The company ranks amongst the leaders in driving the ongoing shift towards renewable energy resources within Canada, having firmly established themselves as one of the leading renewable natural gas (“RNG”) infrastructure platforms within the country. EverGen has done so via an operating model focused around acquiring, developing, owning and operating RNG projects in a bid to supply the North American gas grid with clean energy generated from organic waste. EverGen Infrastructure’s path to becoming one of Canada’s largest RNG platforms, owes its origins to the province of British Columbia’s decision in March 2017 to amend the Greenhouse Gas Reduction Regulation. The amendment, which sought to increase the production and use of renewable gas as well as green and waste hydrogen in British Columbia to simultaneously generate jobs and economic opportunities while reducing GHG emissions, has played a significant role in driving the sector’s growth prospects in recent years. FortisBC has since further reinforced the government ordinance, with the British Columbia-based utility recently revealing that it expects to more than triple its current RNG supply in the coming years. The utility has publicized their vision to have upwards of 75 percent of its total gas supply to be renewable or low carbon by 2050; in the interim, they expect to have 16 million gigajoules of RNG in its system, with contracts in place to procure a further 8 million gigajoules by 2025. Cumulatively, the utility’s RNG supply within the next three years will provide enough energy to meet the natural gas needs of approximately 267,000 homes within BC (https://ibn.fm/zaFDn). EverGen Infrastructure have looked to cater to the ever-increasing RNG demand from FortisBC and other utilities across the nation through the company’s publicly stated goal to own over 20 facilities dotted round the country within five years. Most recently this October, the company announced that the expansion plans for its recently acquired GrowTEC business were nearing completion, with the works adding a further 60,000 gigajoules of RNG to their existing production capacity, taking total production capacity within the operation to 140,000 gigajoules per annum (https://ibn.fm/okc6o). The project will further bolster to EverGen’s existing production capacity, with the latter currently standing at over 230 gigajoules per day of renewable natural gas – the equivalent of powering 100 British Columbia homes for a month. For more information, visit the company’s website at www.EverGenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• A growing chorus of concerns about brain concussions resulting from athletic events is helping to propel new interest in developing pharmaceuticals to treat this “unmet medical need”
• Concussion treatments have largely focused on simple rest, but medical product developer Odyssey Health Inc. is developing a potential treatment to reduce brain inflammation so needed therapy can get to the site of a brain injury
• Odyssey is also developing solutions for other central nervous system troubles, such as the highly fatal childhood disease Niemann-Pick type C, and nerve gas exposure sickness
• The neuropharmaceutical market is forecast to have a great deal of potential, with revenues expected to grow globally from $79.40 billion last year to $125.60 billion by 2029

Concussion head injuries are becoming more widely talked about among sports enthusiasts since two such head injuries in a week’s time required the Miami Dolphins’ quarterback to be carried off the field during a September game and to experience significant memory loss afterward (https://ibn.fm/AiVI6). Football season naturally lends itself to concerns about concussions, known as traumatic brain injuries or TBIs. During November, sports news outlets have discussed player losses suffered by the Dallas Cowboys (https://ibn.fm/9omhC), the Kansas City Chiefs (https://ibn.fm/oTyeX), the Los Angeles Rams (https://ibn.fm/7rr5W), the Detroit Lions (https://ibn.fm/twoPL) and the Minnesota Vikings (https://ibn.fm/ogVqu), but TBIs are also being reported in other sports and in youth leagues, as well as resulting from activities generally not regarded as impact-prone. A high school cheerleader in Texas experienced lasting effects after her third concussion in a year’s time, which led to her being treated for as many as 100 seizures a day, difficulties with balance and visual focusing (https://ibn.fm/KdVwn). Odyssey Health (OTC: ODYY) is clinically testing a novel solution to the potentially devastating effects of TBIs after developing a breath-powered intranasal device that propels a synthetic drug into the nose, where it can be taken up into the brain. The drug sparks gene amplification of anti-inflammatories, antioxidants, and anti-edematous channels, according to the company, inducing an intracellular steroid receptor found in brain cells (https://ibn.fm/TW9ls). Lab tests on animals and humans have demonstrated its safety, and, since animal and cell culture models of neuronal injury have shown positive effects, Odyssey is preparing clinical testing to establish its effectiveness in humans. The effects of concussions can vary from person to person because a TBI affects a wide area of the brain, not just the point of impact. In an attempt to heal itself, the brain requires a high volume of glucose-based energy but the body may have difficulty delivering it because of swelling or related blood flow disruption. Repeat concussions may cause such a significant “energy crisis” that the brain shuts down all but the most essential functions it regulates, which is a major reason athletes are encouraged to rest after an initial injury rather than promptly returning to play, according to academic journal The Conversation (https://ibn.fm/NVuT4). The Conversation’s article notes that, in addition to a lack of pharmaceutical medicine to effectively treat the concerns about TBIs, the effectiveness of some traditional responses is now being disputed by medical science. For example, a long-held belief that a concussion victim should be awakened from sleep every hour may actually inhibit healing for the patient outside of the advent of a severe injury requiring advanced medical attention. And “cocoon therapy’s” complete physical and cognitive rest is now believed to be ultimately harmful to recovery as well. The “unmet medical need” status of TBIs indicates a significant market opportunity for Odyssey Health. Neurological diseases such as Alzheimer’s and psychological disorders and migraines have captured the most attention in the past, but the search for TBI treatments is growing more competitive. Two years ago, the BioPharma Dive journal noted large pharmaceuticals were backing away from brain-related drug development but venture capital investors had been pouring in $1.5 billion to neuroscience in 2018 and analysts were anticipating a new “golden era” for brain-related products in the near future (https://ibn.fm/kglmq). At the same time, an effort to update estimates of the incidence of concussion from all causes diagnosed by all physicians in a large jurisdiction (Ontario), rather than from single causes of injury or small populations, led to the conclusion that approximately 1.2 percent of the population was reporting a concussion at the emergency room annually — the highest rate reported to date (https://ibn.fm/i8dKV). Market researchers at Data Bridge recently forecast the overall global market for neurological disorder drug revenues growing from $79.40 billion last year to $125.60 billion by 2029 at a CAGR of 5.9 percent (https://ibn.fm/4fY0e). In addition to Odyssey’s development of its concussion therapy, the company has been working on solutions for central nervous system maladies such as the highly fatal childhood disease Niemann-Pick type C and nerve gas exposure sickness. Last month, Odyssey announced the formation of a subsidiary (Odyssey Neuropharma, Inc.) focused on the development of Odyssey’s neurosteroid solutions to advance the treatment of these disorders (https://ibn.fm/mcdB7). For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Governments are taking action to regulate, limit, or eliminate the use of third-party cookies that collect user information
• The European Union ePrivacy Directive requires parties to obtain user consent before sending cookies
• Google intends to phase out support for third-party cookies from its Chrome browser in 2024
• Reklaim’s fully consensual, consumer-verified data ecosystem offers a high-quality, fully compliant solution to advertisers and data companies while rewarding users for providing access to data

The online advertising industry is transforming rapidly as governments take action to regulate, limit, or eliminate the use of third-party cookies. As a result, Reklaim (TSX.V: MYID) (OTCQB: MYIDF) is strongly positioned to serve marketers’ needs by offering fully-compliant data solutions while rewarding consumers for providing access to their data through its mobile identity ecosystem.

Cookies are small text files websites send to devices that mine and store data from the user’s browsing activities. While the cookies themselves cannot harm the device, they can store enough data to potentially identify and track users across the internet.

Some cookies — such as those that hold items in an online shopping cart — are necessary to enhance the e-commerce experience. Others, such as marketing cookies, track online activity to deliver relevant advertising based on the user’s browsing history. Marketing cookies share user information with other organizations, allowing these companies to ‘bid’ on consumers’ data profiles before serving them an advertisement.

Advertisers and brands leverage a wide range of data mined by marketing cookies, including user clicks, e-commerce preferences, location, and search history. To protect user privacy, the European Union passed the ePrivacy Directive (“EPD”) in 2002, requiring parties to (a) obtain consent before sending cookies, (b) provide detailed information about the data tracked before requesting permission, and (c) allow users to withdraw consent (https://ibn.fm/zlZiN) easily. Similar laws worldwide have either been passed or are currently under investigation, including in the United Kingdom (https://ibn.fm/CbSqx) and Germany (https://ibn.fm/sDw4Y), and the state of California (CCPA/CPRA), by far the most disruptive to the data ecosystem.

In addition to government regulations, tech companies are developing privacy-first alternatives to regulate or eliminate third-party cookies. One example is Google’s plan to phase out support for third-party cookies from its Chrome browser in late 2023 (https://ibn.fm/6888x), while Apple introduced the removal of device tracking in 2021 via its Advanced Ad Tracking Tool.

With both a cookie and device tracking future rapidly emerging, brands and advertisers are looking for new options. Reklaim aims to fill that void with addressable consumer-verified data generated in an ecosystem that rewards users for sharing valuable information about their shopping habits and brand preferences.

Reklaim’s data solutions offer more than just compliance. The data generated through its platform is current, high quality, and of greater relevance because users are actively choosing to share their information. By offering compliant, first-party data to brands, advertisers, and data companies, Reklaim is filling a void that regulators have created while allowing consumers to take control of their online input by receiving compensation.

For more information, visit the company’s website at www.ReklaimYours.com.

NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications
• Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after
• These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of blood pressure in the patient population over multiple weeks
• There is an established link between hypertension and vascular dementia, along with hypertension being twice as frequent in people with diabetes and hypertensive patients being at greater risk of developing diabetes
• The success of these two studies will draw Lexaria closer to tapping into the dementia drug market, which is projected to hit $32.3 billion by 2030, and the diabetes drug market, which is expected to reach $82.92 billion by 2027

Lexaria Bioscience (NASDAQ: LEXX) just announced two notable studies, DEM-A22-1, and DIAB-A22-1, on dementia and diabetes, respectively, scheduled for completion in January 2023. The studies seek a deeper understanding of the company’s patented DehydraTECH(TM)-processed CBD for its potential therapeutic utility against both conditions (https://ibn.fm/Uta3i). According to John Docherty, Lexaria’s President and Head of Research, these studies will build on the just-concluded hypertension clinical study whose results he referred to as “truly exceptional.”  The study demonstrated a statistically significant lowering of blood pressure in the patient population over multiple weeks, something that, Docherty noted, other entities using other oral CBD formulations have failed to replicate or even evidence. “The study demonstrated excellent safety and tolerability of DehydraTECH-CBD and no adverse changes in liver enzymes throughout the study, a common concern in CBD dosing. We were also able to show that decreases in blood pressure were similar in participants currently taking standard of care hypertension medications to those not undergoing any concurrent blood pressure treatment,” he noted. There is an established link between hypertension and vascular dementia. In addition, hypertension is twice as frequent in people with diabetes, and hypertensive patients are at greater risk of developing diabetes. Lexaria looks to draw from the success of its hypertension clinical study to show DehydraTECH-CBD’s potential to offer potential therapeutic utility against these two conditions. Currently, dementia is ranked as the seventh leading cause of death among all diseases, accounting for 40 out of every 100,000 deaths in the United States (https://ibn.fm/V8TiC). It also currently affects seven million Americans and has a significant unmet need that Lexaria hopes to meet. Diabetes, on the other hand, ranks as the eighth leading cause of death in the United States, accounting for 31 out of every 100,000 deaths in the country (https://ibn.fm/ACcAT). Over 37.3 million people, representing 11.3% of the country’s population, live with the condition, yet few viable treatment options are available for them (https://ibn.fm/3O03G). CBD has, so far, shown some ability to reduce the incidence of diabetes in mice due to its powerful anti-inflammatory and antioxidant properties. In addition, Lexaria has proven DehydraTECH’s ability to cross the blood-brain barrier effectively. As such, it is optimistic that it will achieve potential treatment for both dementia and diabetes. “We are excited to investigate whether DehydraTECH-CBD has a potential application in the treatment of dementia and diabetes based on its propensity to cross the blood-brain barrier, the fact that DehydraTECH-CBD lowers human blood pressure, and the fact that CBD is known to have vasodilatory, anti-inflammatory and antioxidant effects,” noted Mr. Docherty. The two studies will be undertaken by leading third-party testing laboratories in Canada, with analysis and reporting set to follow their scheduled completion in January 2023. Their success will draw Lexaria closer to tapping into the dementia drug market, projected to hit $32.3 billion by 2030, and the diabetes drug market, which is expected to reach $82.92 billion by 2027. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The Inflation Reduction Act (“IRA”), a linchpin to the U.S. meeting its emissions goals, includes $369 billion dedicated to expanding renewable energy
• The new bill is projected to generate $600 billion in capital investment, 550,000 clean energy jobs, and 525-550 gigawatts of new clean power
• The passage of the IRA served as a catalyst to solar stocks and continues to grow interest in upstarts like GeoSolar Technologies

President Joe Biden is on a mission to cement his legacy as an ambassador of all things anti-climate change. The passage of the Inflation Reduction Act will forever be his key piece of legislation as he doubled down on America meeting its emissions targets. The administration’s efforts are good for solar stocks from up-and-comers like GeoSolar Technologies (“GST”) to established brands like First Solar (NASDAQ: FSLR) and the loyal solar investment community that has endured over the last decade as solar builds momentum.

“We’re proving that good climate policy is good economic policy,” said President Biden in a speech at the COP27 climate negotiations in Egypt. Biden emphasized, “The United States of America will meet our emissions targets by 2030.” The country has a promised to cut greenhouse gas emissions by at least half compared to 2005 levels by the end of this decade, which means an acceleration in efforts considering the current trajectory has the U.S. reducing emissions by just under 40 percent by 2030.

The U.S. is the second biggest emitter of greenhouse gases in the world, trailing only China. The recently passed Inflation Reduction Act (“IRA”) earmarks $369 billion to expand renewable energy over the next 10 years, the nation’s biggest commitment ever to alternative energies like wind, solar, and electric vehicles. Notably, the IRA adds tailwinds in American trends to reduce dependence on China for alternative energy products. Tariffs on Canadian products have been lifted and incentives abound encouraging companies and consumers to shift away from fossil fuels.

The American Clean Power Association estimates that the IRA will generate $600 billion in capital investment, while creating 550,000 clean energy jobs and 525-550 gigawatts of new clean power.

Investors piled into depressed alternative energy stocks as it became increasingly clear that the IRA was going to be passed. This was evident in money rotation in exchange trading funds (“ETFs”) flipping from net outflows of $223 million in the two weeks prior to news of a Congressional agreement on the IRA July 27 to $433 million of net inflows, according to Morningstar data.

Subsequent to the lawmakers’ pact in July ahead of the IRA bill becoming law, individual solar stocks have performed well. First Solar shot from $70 in July to $161 in November. Enphase (NASDAQ: ENPH) is up approximately 85%, SunPower (NASDAQ: SPWR) has gained 37%, and Array Technologies (NASDAQ: ARRY) has surged 67%, amongst others.

Rising interest rates have not had much of a negative impact on solar stocks either. Now, with the Democrats keeping control of the Senate, the cheers for solar could get louder. Against this backdrop, GeoSolar Technologies eyes a public listing. Denver-based GeoSolar is the creator of the SmartGreen(TM) Home system (all-electric) that harnesses the power of the earth and sun to let people own their own green energy system and disconnect from the utility grid.

The company was founded in 2020 by an elite team of respected climate scientists for the purpose of making a meaningful impact on climate change. In that effort, the team developed an all-house solution featuring solar and geothermal technologies that is suitable for warm and cold climates, new construction, renovations, and retrofits.

A SmartGreen(TM) home is the epitome of efficiency. GeoSolar ensures the envelope (the exterior walls and attic are properly insulated to keep the outside temperature out and inside temperature consistent. The system involves using all electric appliances and mechanicals (no propane or natural gas allowed) because the heart of a SmartGreen(TM) home is on the roof in the form of a photovoltaic solar panel system. The solar panels provide all the electricity the home requires, including optional electric vehicle charging stations also provided and installed by GeoSolar.

Heating and cooling utilize geothermal, which involve installing underground piping, called ground loops. Ground loops are run at a depth where temperatures are consistent year-round. In this capacity, the earth serves as a heat source or heat sink, depending on if heating or cooling is required, as a critical part of an electric geothermal heat pump system.

GeoSolar’s SmartGreen(TM) homes also feature a CERV® Air Filtration systems that provide ultra-clean air free of pollutants and pathogens, including SARS-CoV-2, the coronavirus responsible for COVID-19. GeoSolar handles the complete process from design through construction and even assists with 100% financing options and any tax deductions and government incentives available.

The whole patent-pending process to flip to all natural energy resources can be completed in a few weeks. The first SmartGreen(TM) homes have been constructed in GeoSolar’s home state that is known to have hot summers and snowy winters where they have received some of the highest scores in the industry standard Home Efficiency Rating System (“HERS”).

As it raises money via a Regulation A+ capital offering and readies to join the public domain, GeoSolar has the fundamentals in place to expand its geographical footprint that includes some 84 million outdated homes with obsolete, pollutive, fossil fuel-powered energy systems and 1.4 million new homes constructed each year.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Corporations worldwide are working to improve their climate friendliness through a variety of environmental, social and governance (“ESG”) factors
• U.S. distributed energy solutions innovator Correlate Infrastructure Partners Inc. is a company working strategically with clients to assess their energy emissions profile and identify possible improvements and funding opportunities for those improvements
• CIPI’s advisement helps clients achieve transparency in their ESG responsibility and to make improvements in a cost-beneficial manner
• CIPI has realized record revenues during the most recent quarter as a result of its operations and still has $16.2 million in unrecognized revenues anticipated from work currently under way

Environmental, social and governance (“ESG”) responsibility has come to define corporate attention to climate change and steady drive toward clean energy adoption. While nearly a decade has passed since some 200 international entities and their governments forged a compact for reducing fossil fuel dependence and analysts expect several more to pass before meaningful progress becomes apparent, improvements are under way (https://ibn.fm/Jt8QL).

One entity helping to advance progress on the greenhouse gas reduction front is a tech-enabled development, finance, and fulfillment platform from Correlate Infrastructure Partners (OTCQB: CIPI). The company is making it easier and cost effective for those in the commercial real estate industry to acquire the necessary solutions for solar, cogeneration, energy storage, and electric vehicle infrastructure, as well as driving intelligent efficiency retrofits for community-scale applications.

The key for companies to open the door to ESG success is to first evaluate their current energy use and emissions profile and identify key stakeholders who will be vital to advancing any strategy toward new targets. Correlate Infrastructure provides proprietary analytics and advisement for companies seeking to reduce the carbon footprint of their buildings before helping clients navigate the tricky journey toward managing and financing infrastructure improvements for a better and more affordable ESG outcome.

“Correlate Infrastructure Partners is making energy management and procurement transparent and cost-effective as we digitize the process that has been archaic for way too long,” CEO Todd Michaels stated earlier this year (https://ibn.fm/Rsdg7). “We are excited to be at the forefront of an industry that is at an inflection point, and we are eager to begin working to change the way commercial real estate owners optimize energy assets.”

To be effective in reducing their carbon emissions, companies need to consider not only the facilities they control directly, but also the impact of the utilities they purchase and other indirect expressions of their energy use profile upstream and downstream from their operations.

Once the elements of a reduced-emissions profile are identified and a strategy established, companies can begin working toward acquisition of necessary resources for on-site renewables or power purchase agreements as appropriate, reporting progress according to company standards and communicating that progress to the public.

Correlate’s ability to provide clients with distributed energy solutions that come with smart cost-reduction incentives and associated financing has led to record revenues for the most recently reported quarter. In addition, the company has another $16.2 million in unrecognized revenues anticipated from work that is currently under way. Overall, the company foresees project opportunities valued at up to $194 million.

For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

RHK Capital is organizing the RHK Capital 2022 Disruptive Growth Conference, at the offices of Reed Smith, NYC. Spread over two days on December 5-6, 2022, investors, brokers, wealth managers, capitalists, growth companies and enterprises, are invited to attend this interactive learning and network-building conference in person or via webcast. The focus of RHK Capital in this in person and webcast conference is to spotlight aspiring companies and young industries with disruptive growth potential.

The RHK Capital 2022 Disruptive Growth Conference is attended by over 200 institutional investors, accredited investors, family offices, Wall Street analysts, financial advisors, broker-dealer wealth managers, and RHK clients. Up to 30 senior company executives pitch their business ideas and host engaging presentations in front of industry leaders and investors.

The RHK 2022 conferences are well-researched events that showcase the best talent in areas of communications, consumer, healthcare, energy or alternative energy, natural resources, life sciences, and technology. They bring deserving companies to the forefront of the most influential and important investors in their spectrum. On the other end, RHK Capital Conferences offer investors new investment avenues and innovative ideas.

This is an important forum for investors to discover and do business with disruptive growth companies. As RHK Capital Conferences are well-curated events, the team understands the requirements of the companies and interested investors. They guide and direct activities to encourage creative communication and connections.

The conference days will feature panel discussions, one-to-one sessions, and interactive networking among the companies. Young enterprises can meet and connect with other participants to discuss the specific challenges and opportunities in their niche areas.

As emerging growth companies pave the way for novel ideas and innovation, investors can leverage this opportunity and provide support to help them reach their full potential more quickly, profiting as early participants. Along with the learning sessions at this conference, enterprises, growth companies, and investors can collaborate and grow together in these quickly changing times.

To learn more, please visit https://ibn.fm/eAtz4.

Become a part of the 2023 U.S. debut of Lift Events & Experiences, at the Moscone Center in San Francisco, from Wednesday, August 2 – Friday, August 4, 2023. The leader in Canada, Lift’s first conference over the border offers exclusive content, robust networking, and unparalleled new product discovery opportunities. The event is dedicated to the evolution of the cannabis industry, and brings to the U.S. Lift’s long-established and respected reputation for powerful cannabis events.

After proving its mettle in Vancouver and Toronto, the former Lift&Co. Expo will now simply be called ‘Lift’, reflecting its expanding footprint. Lift invites attendees for unique and immersive learning experiences in 2023, including Lift Vancuover (January 12-14, 2023), Lift Toronto (June 1-3, 2023) and at the new Lift San Francisco event (August 2-4, 2023). With Lift now expanding its coverage to the U.S., the ties between the U.S. West Coast and Western Canada’s long-thriving cannabis culture are expected to strengthen further.

“Lift welcomes everyone, from legacy participants to multistate operators to everyday folks who enjoy and respect the plant,” says Lift Events & Experiences Portfolio Lead, Lindsay Roberts. “We’re producing a year of shows that care for the specific needs of each segment of the cannabis community while inspiring an exciting future. To emphasize this commitment, we’re dropping our old ‘&Co. Expo’ moniker to put the focus simply on ‘Lift’ as we work to affect positive change across North America.”

Lift events are attended by cannabis industry veterans and fresh voices alike, always presenting valuable and updated information through speaker sessions and presentations on topics vital to the cannabis business and trade. Connect with cannabis experts, innovators, regulators, and leaders of the cannabis business community, build long-term business ties, and get discovered by potential investors on this robust networking forum.

Through one-on-one interactions and communication, the Lift team ensures that every company or individual attending the event is presented with an abundance of opportunities, including growers, brands and product delivery, advocacy and investment, legal/compliance, retailers, budtenders, enthusiasts and more.

For more information on Lift Events & Experiences, visit https://liftevents.com/.

• CubCrafters’ announcement about filing for Reg A qualification with the SEC was met with enthusiasm as investors pledged $5 million in reservations for 1 million planned shared in the first 48 hours following the announcement
• The company intends to use some of the infusion of funding to accelerate production rates as they are sold out through late-2024and anticipate taking orders for 2025 soon
• The backcountry aircraft market is expected to reach $11.9 billion by 2030
• CubCrafters company focuses on four main product lines – the Carbon Cub FX, NXCub, XCub, and Carbon Cub EX kits, and announced a new engine option in August 2022

The light and ultralight aircraft market is projected to grow from $7.5 billion in 2022 to $11.9 billion in 2030, driven by the number of backcountry enthusiasts growing on the heels of the COVID-19 pandemic (https://ibn.fm/xH1g2). “Light aircraft” is classified as any aircraft with a maximum gross takeoff weight of 12,500 pounds or less and are most commonly used for general aviation purposes. Best-in-class backcountry aircraft producer CubCrafters is leveraging the anticipated industry growth after announcing its intentions of a public offering under Reg A qualifications with the U.S. Securities and Exchange Commission (“SEC”).

Within the first 48 hours of the company’s announcement, CubCrafters was met with enthusiastic investor interest, with $5 million in reservations for 1 million planned shares, growing to over $25 million in reservations and is on track to reach its planned $50 million target as it awaits qualification for its listing with the SEC.

CubCrafters was founded in 1980 by Jim Richmond after a thorough fact-finding mission in Alaska, resulting in selling his home insulation business and switching to rebuilding Super Cubs. The company is driven by Jim’s vision and the ability to optimize performance potential of the Super Cub legacy. CubCrafters introduced its first new aircraft in 1999, the Piper/CubCrafters PA18, built under the FAA’s Spare & Surplus Rule.

The company focuses on four main product lines – the Carbon Cub FX, NXCub, XCub, and Carbon Cub EX kits. The models are built to be lightweight and powerful, with some emphasizing short take-off and landing capabilities, and others built for longer missions in unforgiving backcountry environments. Dominating this sector, the company has developed seven models that emphasize flexibility, including varied landing gear configurations such as nosewheel, tailwheel, floats, and skis.

In the Reg A announcement, Vice President of Sales and Marketing Brad Damm discussed how CubCrafters plans to use an infusion of funding to accelerate the production rate, making special note that the company has already sold out through late-2024 and is expecting to begin taking orders for 2025. (Source)

In August, the company debuted a new lightweight engine for its Carbon Cub model, improving the CC340 that made previously unheard-of short takeoff and landing performance possible for backcountry enthusiasts. The new CC363i F/P is a higher displacement fuel-injected engine with more horsepower than the CC340, according to CubCrafters. As the flight test program is nearing completion, new engines will begin shipping to customers, with priority given to those wishing to upgrade their existing kit aircraft order.

“This is an engine our customers have been specifically asking for, especially our kit aircraft customers. It’s simple to operate and has better overall performance than any of the other fixed-pitch engines we offer,” said Damm, who flew the first CC363i F/P equipped Carbon Cub (https://ibn.fm/Qmih4). “It’s smoother, more fuel efficient, and it cools better. Customers who choose this new engine are going to be pleased for sure.”

For more information, visit the company’s website at www.CubCrafters.com.

NOTE TO INVESTORS: The latest news and updates relating to CubCrafters Inc. are available in the company’s newsroom at https://ibn.fm/CUB